**Clairity, Inc.** develops Clairity Breast, an FDA-authorized AI platform that predicts a woman's five-year breast cancer risk from routine screening mammograms by analyzing tissue patterns. The company targets U.S. healthcare providers, with partnerships including Beth Israel Deaconess Medical Center in Boston and planned expansions in Colorado and Georgia; it operates initially via a self-pay model while pursuing insurance reimbursement. Clairity Breast was trained on over 450,000 mammograms and validated on 77,000 more with outcome data from five screening centers. Founded in 2020 by breast imaging specialist Connie Lehman of Mass General Brigham, the Boston-based firm is led by CEO Jeff Luber. It raised $43 million in a Series B round backed by Sante Ventures and ACE Global Equity, plus later funding from the Breast Cancer Research Foundation in 2025 to support commercialization of Clairity Breast and development of Clairity Breast 3D and Clairity Heart.